Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3772 vs PCV13 in Toddlers
NCT04525599Phase 1Completed
- Sponsor
- Affinivax, Inc.
- Start
- Sep 2020
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AFX3772 in pneumococcal disease (6 arms), sponsored by Affinivax, Inc. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Body Temperature Abnormalities and/or Adverse Events and 2 more. Started Sep 2020; status: completed.
02
Drugs
AFX3772
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT04525599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525599.